Fig. 2From: Efficacy and safety of osimertinib for leptomeningeal metastases from EGFR-mutant non-small cell lung cancer: a pooled analysisMeta-analysis of ORR, DCR, and one-year OS of osimertinib for the treatment of LM from EGFR-mutant NSCLC. a ORR; b DCR; c one-year OSBack to article page